v3.25.2
Note 13 - Segment Reporting
6 Months Ended
Jun. 30, 2025
Notes to Financial Statements  
Segment Reporting Disclosure [Text Block]

13.

Segment Reporting

 

The Chief Operating Decision Maker is the Chief Executive Officer, who reviews the segment operating results in order to allocate resources and assess performance.

 

The Company has identified three segments:

 

(1) Electric vehicles,

 

(2) Medical supplies and

 

(3) Drones 

 

The electric vehicle segment consists of sales of commercial electric vehicles to customers. A significant portion of such sales are through state subsidized or funded programs. The medical supplies segment consists solely of sales to Maddox Defense, a related party based on an agreement to supply refurbished medical gowns on a cost-plus pricing arrangement. Through the Company's drone operations, it is also diversifying its portfolio of assets by engaging in the future production and supply of drones that will be used in the agricultural environment. Currently, activity within the Drones segment is limited to start up expenses and research and development activities.

 

The table below summarizes the operating results of the Company's segments for the three and six months ended June 30, 2025: 

 

  

Electric vehicles

  

Medical Supplies

  

Drones

  

Total

 

Sales, net

 $(25,237) $1,072,266  $-  $1,047,029 

Operating loss

 $(3,274,582) $(951,437) $(573,607) $(4,799,626)

Interest income (expense), net

              303 

Unrealized loss on financial instruments at fair value

              (290,144)

Realized loss on conversion of convertible notes

              (76,764)

Other expense

              19,494 

Income tax expense

              - 

Net loss

             $(5,146,737)

 

  

Six months ended June 30th , 2025

 
  

Electric vehicles

  

Medical Supplies

  

Drones

  

Total

 

Sales, net

 $348,063  $1,289,532  $-  $1,637,595 

Operating loss

 $(16,524,991) $(1,339,675) $(666,634) $(18,531,300)

Interest income (expense), net

              11,056 

Unrealized loss on financial instruments at fair value

              (573,937)

Realized loss on conversion of convertible notes

              (76,764)

Other expense

              (12,173)

Income tax expense

              - 

Net loss

             $(19,183,118)